IL4R and chronic obstructive pulmonary disease: Moreover, phase-3 trials in biomarker-enriched COPD populations have shown reduced exacerbations with dupilumab (anti-IL-4Rα) and mepolizumab (anti-IL-5) added to optimized inhaled therapy, marking tangible progress for the eosinophil/type-2–high endotype.